Almstead Neil Gregory, an insider at PTC Therapeutics Inc (PTCT), sold 101,199 shares of the company's stock on November 24, 2025, at a price of $83.44 per share, amounting to a total transaction value of $8.44 million. Following this sale, Gregory retains 101,199 shares in the company.
PTC Therapeutics, headquartered in Warren, New Jersey, is a biopharmaceutical firm focused on developing and commercialising medicines for rare disorders. The company has a market capitalisation of $6.9 billion and a price-to-earnings ratio of 9.21, with an earnings per share figure of 8.53.
Insider transactions, such as this sale, are reported to the SEC and provide transparency regarding how executives and board members view their stock holdings. While such sales can stem from various motivations, including tax planning or personal financial needs, they do not necessarily indicate a negative outlook on the company. Investors are advised to consider broader patterns of insider activity over time rather than focusing solely on individual transactions.
PTC Therapeutics has upcoming earnings reports scheduled for May 4, 2026, with an estimated EPS of $-0.64 and revenue of $204.8 million, followed by another report on August 5, 2026, with an estimated EPS of $-0.54 and revenue of $222.6 million.